Amicus Therapeutics Announces First Patient Dosed in Phase 3 PROPEL Pivotal Study of AT-GAA in Patients with Pompe Disease
pharmaceutical investing Amicus Therapeutics Announces Approval of Galafold® (Migalastat) for Fabry Disease in Japan
U.S. FDA Files New Drug Application Under Priority Review for Migalastat for Treatment of Fabry Disease
Steadright Critical Minerals Inc. to Acquire up to 75% Interest in the Péribonka Ree-Niobium Carbonatite Project, Saguenay-Lac-St-Jean Region, Québec
Prismo Metals Announces Listing of Blade Resources on the CSE Prismo Metals Owns 6,755,000 Shares of Blade Resources
Goldgroup Highlights Its Two Producing Mines and Significant Growth Potential Across the Don David Gold Complex in Mexico